Alex Friedlaender

4.2k total citations · 2 hit papers
86 papers, 2.3k citations indexed

About

Alex Friedlaender is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alex Friedlaender has authored 86 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 48 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Alex Friedlaender's work include Lung Cancer Treatments and Mutations (37 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Lung Cancer Research Studies (20 papers). Alex Friedlaender is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Cancer Immunotherapy and Biomarkers (31 papers) and Lung Cancer Research Studies (20 papers). Alex Friedlaender collaborates with scholars based in Switzerland, United States and Italy. Alex Friedlaender's co-authors include Alfredo Addeo, Giuseppe Luigi Banna, Glen J. Weiss, Umberto Malapelle, Maxime Borgeaud, Vivek Subbiah, Alessandro Russo, Michel Obéid, Solange Peters and Alexander Drilon and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Alex Friedlaender

83 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

2021 157 citations Maxime Borgeaud, Alfredo Addeo et al. World Journal of Clinical Oncology profile →
Oncogenic alterations in advanced NSCLC: a molecular super-highway

2024 47 citations Alex Friedlaender, Giuseppe Luigi Banna et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alex Friedlaender Switzerland	28	1.5k	1.1k	711	437	263	86	2.3k
Meghan J. Mooradian United States	19	1.8k 1.2×	1.2k 1.1×	472 0.7×	282 0.6×	290 1.1×	68	2.6k
Dickran Kazandjian United States	21	1.5k 1.1×	863 0.8×	952 1.3×	423 1.0×	414 1.6×	83	2.7k
Sun Min Lim South Korea	27	1.5k 1.0×	1.6k 1.5×	900 1.3×	521 1.2×	206 0.8×	132	2.8k
W. Jeffrey Petty United States	28	1.2k 0.8×	1.0k 0.9×	886 1.2×	188 0.4×	325 1.2×	110	2.6k
Antonio Passaro Italy	28	2.1k 1.4×	2.2k 2.0×	1.0k 1.4×	741 1.7×	265 1.0×	120	3.4k
Francesco Passiglia Italy	26	1.4k 0.9×	1.2k 1.0×	814 1.1×	629 1.4×	202 0.8×	104	2.4k
Adam J. Schoenfeld United States	23	1.5k 1.0×	1.0k 0.9×	576 0.8×	330 0.8×	477 1.8×	77	2.3k
Erika Rijavec Italy	24	1.1k 0.7×	707 0.6×	489 0.7×	420 1.0×	253 1.0×	93	1.7k
Kathryn C. Arbour United States	21	2.5k 1.7×	1.8k 1.6×	1.3k 1.9×	747 1.7×	448 1.7×	53	3.8k
William J. Edenfield United States	19	783 0.5×	741 0.7×	674 0.9×	168 0.4×	187 0.7×	101	2.1k

Countries citing papers authored by Alex Friedlaender

Since Specialization

Citations

This map shows the geographic impact of Alex Friedlaender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Friedlaender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Friedlaender more than expected).

Fields of papers citing papers by Alex Friedlaender

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Friedlaender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Friedlaender. The network helps show where Alex Friedlaender may publish in the future.

Co-authorship network of co-authors of Alex Friedlaender

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Friedlaender. A scholar is included among the top collaborators of Alex Friedlaender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Friedlaender. Alex Friedlaender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borgeaud, Maxime, et al.. (2024). Management of stage III non-small-cell lung cancer: rays of hope. SHILAP Revista de lepidopterología. 5(1). 85–95. 3 indexed citations

Montemurro, Michael, et al.. (2023). Precision Oncology in Gastrointestinal Stromal Tumors. Current Oncology. 30(5). 4648–4662. 8 indexed citations

Sandoval, José Luís, et al.. (2023). Neoadjuvant Immunotherapy: A Promising New Standard of Care. International Journal of Molecular Sciences. 24(14). 11849–11849. 17 indexed citations

Addeo, Alfredo, Petra den Hollander, Alex Friedlaender, et al.. (2023). RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives. Pharmacology & Therapeutics. 242. 108344–108344. 21 indexed citations

Borgeaud, Maxime, José Luís Sandoval, Michel Obéid, et al.. (2023). Novel targets for immune-checkpoint inhibition in cancer. Cancer Treatment Reviews. 120. 102614–102614. 76 indexed citations

Rebuzzi, Sara Elena, Arsela Prelaj, Alex Friedlaender, et al.. (2022). Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Critical Reviews in Oncology/Hematology. 179. 103806–103806. 19 indexed citations

Parikh, Kaushal, Giuseppe Luigi Banna, Stephen V. Liu, et al.. (2022). Drugging KRAS: current perspectives and state-of-art review. Journal of Hematology & Oncology. 15(1). 152–152. 85 indexed citations

Friedlaender, Alex, Jarushka Naidoo, Giuseppe Luigi Banna, et al.. (2022). Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treatment Reviews. 104. 102350–102350. 31 indexed citations

Giunta, Emilio Francesco, Alessio Signori, Howard West, et al.. (2022). Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer. Frontiers in Oncology. 12. 921854–921854. 5 indexed citations

10.

Laubscher, Florian, Samuel Cordey, Alex Friedlaender, et al.. (2021). SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical Cohort. Microorganisms. 9(10). 2145–2145. 2 indexed citations

11.

Addeo, Alfredo, Alex Friedlaender, Giuseppe Luigi Banna, & Glen J. Weiss. (2021). TMB or not TMB as a biomarker: That is the question. Critical Reviews in Oncology/Hematology. 163. 103374–103374. 154 indexed citations

12.

Aliaga, Pamela Trillo, Dario Trapani, José Luís Sandoval, et al.. (2021). Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. Cancers. 13(22). 5829–5829. 10 indexed citations

13.

Rundo, Francesco, Melissa Bersanelli, Alex Friedlaender, et al.. (2021). Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy. Clinical Genitourinary Cancer. 19(5). 396–404. 13 indexed citations

14.

Borgeaud, Maxime, et al.. (2021). Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World Journal of Clinical Oncology. 12(4). 217–237. 157 indexed citations breakdown →

15.

Péron, Julien, Alex Friedlaender, Valeria Viassolo, et al.. (2020). Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Scientific Reports. 10(1). 7073–7073. 72 indexed citations

16.

Friedlaender, Alex, Alexander Drilon, Glen J. Weiss, Giuseppe Luigi Banna, & Alfredo Addeo. (2020). KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. Cancer Treatment Reviews. 85. 101978–101978. 91 indexed citations

17.

Friedlaender, Alex, Stephen V. Liu, Antonio Passaro, et al.. (2020). The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. Clinical Lung Cancer. 21(6). e539–e543. 16 indexed citations

18.

Friedlaender, Alex, et al.. (2020). Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer. ESMO Open. 5(Suppl 4). e000796–e000796. 75 indexed citations

19.

Friedlaender, Alex, Giuseppe Luigi Banna, Sandip H. Patel, & Alfredo Addeo. (2019). Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC. Current Treatment Options in Oncology. 20(10). 79–79. 31 indexed citations

20.

Friedlaender, Alex, Giuseppe Luigi Banna, Umberto Malapelle, Pasquale Pisapia, & Alfredo Addeo. (2019). Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?. Frontiers in Oncology. 9. 166–166. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact